Grissinger Michael 4
4 · Aprea Therapeutics, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Aprea (APRE) Director Michael Grissinger Receives Award
What Happened
Michael Grissinger, a director of Aprea Therapeutics (APRE), received equity awards on June 16, 2026 totaling 15,690 units: 3,135 shares granted as restricted stock units (RSUs) and 12,555 units reported as a derivative award. Both awards were granted at $0.00 (no cash paid) and have no immediate realized value at grant.
Key Details
- Transaction date: 2026-06-16; filing date: 2026-06-17 (timely filing).
- Grants: 3,135 RSUs @ $0.00; 12,555 derivative units @ $0.00. Total units granted = 15,690. Total immediate cash value = $0.
- Shares owned after transaction: not specified in the provided filing.
- Footnotes:
- F1: The 3,135 RSUs were granted 6/16/2026 and will vest and be settled in common stock on 6/16/2027, subject to continued board service and possible acceleration.
- F2: The 12,555 derivative award vests in full on 6/16/2027, subject to continued board service and possible acceleration.
- Transaction type code: A (award/grant). Not a sale or open-market purchase.
Context
These awards are time-based grants that vest one year after the grant date if the director remains in service (with possible acceleration under certain conditions). Because they are not purchases or sales and have no immediate cash value, they do not directly signal buying or selling sentiment; they are standard compensation/retention awards for insiders.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-16+3,135→ 6,024 total - Award
Stock Options (Right to Buy)
[F2]2026-06-16+12,555→ 12,555 totalExercise: $0.73Exp: 2036-06-16→ Common Stock (12,555 underlying)
Footnotes (2)
- [F1]These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
- [F2]The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.